Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2805466 | 1.00 | POLB (0.53) | POLBNQO2ESR1LMNAMAPT | |
| SCHEMBL11066332 | 0.84 | POLB (0.53) | POLBNQO2LMNAMAPTKMT2A | |
| SCHEMBL11076121 | 0.84 | POLB (0.53) | POLBNQO2LMNAMAPTKMT2A | |
| SCHEMBL11066346 | 0.84 | POLB (0.53) | POLBNQO2LMNAMAPTKMT2A | |
| SCHEMBL11083064 | 0.82 | POLB (0.51) | POLBKMT2AMEN1TP53ALOX15 | |
| SCHEMBL11080951 | 0.82 | POLB (0.65) | POLBLMNAMAPTKMT2AMEN1 | |
| SCHEMBL11087637 | 0.82 | POLB (0.51) | POLBMAPTKMT2AMEN1CYP3A4 | |
| SCHEMBL11083067 | 0.82 | POLB (0.51) | POLBKMT2AMEN1TP53ALOX15 | |
| SCHEMBL8303787 | 0.82 | POLB (0.65) | POLBLMNAMAPTKMT2AMEN1 | |
| SCHEMBL1239325 | 0.82 | POLB (0.51) | POLBLMNAMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MERCK & CO., INC. | 2010-09-23 | — | — | US | disclosed |
| EP-1981509-B1 | Pyrazolo[1,5-a]pyrimidine derivatives for use in treatment of Alzheimer's disease and related conditions | MERCK SHARP & DOHME (GB) | 2010-03-17 | — | — | EP | disclosed |
| EP-1981509-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | Merck Sharp & Dohme Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085873-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-02 | — | — | WO | disclosed |
| US-4465630-A | Tetraazaannulene cobalt complex compounds and method for preparation therefor | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1984-08-14 | — | — | US | disclosed |
| EP-0073456-A1 | Tetraazaannulene cobalt complex compounds and method for preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MAPT, MAP2, TTBK1 | POLB 2793/4885NQO2 3866/4885ESR1 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.